medigraphic.com
ISSN 1561-3046 (Electronic)

2013, Number 1

<< Back Next >>

Rev Cub Med Mil 2013; 42 (1)

Higeia or Panacea for treating non alcoholic fatty liver disease

Mulet PA, Pérez LM, Gámez EM, Mulet GA

Language: Spanish
References: 35
Page: 80-93
PDF size: 74.93 Kb.


ABSTRACT

Non alcoholic fatty liver disease is the most frequent chronic liver condition in the world. As in other chronic non-communicable diseases, treatment has used both pharmacological and non-pharmacological resources. In order to estimate the use and value of each current therapeutic approach, a revision for updating on this topic is conducted. Published evidence were reviewed, mainly articles on gastroenterology and other specialties dealing with the topic and which are available in electronic databases.


REFERENCES

  1. McNear S; Harrison S. Current Status of Therapy in Nonalcoholic Fatty Liver Disease; Ther Adv Gastroenterol. 2009;2(1):29-43.

  2. Day C, James O. Steatohepatitis: a tale of two "hits"? Gastroenterology. 1998;114:842-5.

  3. Diehl AM, Li ZP, Lin HZ, Yang SQ. Cytokines and the pathogenesis of non-alcoholic steatohepatitis. Gut. 2005;54:303-6.

  4. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Taniai M, Hasegawa K, Okuda H, Hayashi N, et al. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol. 2002;37:154-60.

  5. Oh MK, Winn J, Poordad F. Review article: Diagnosis and treatment of Non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2008(5):503-22.

  6. Carter-Kent C, Zein N, Feldstein A. Cytokines in the pathogenesis of fatty liver and disease Progression to Steatohepatitis: Implications for Treatment. Am J Gastroenterol. 2008;103 (4):1036-42.

  7. Soto González A; Prada Vigil A; Delgado Blanco M; Buńo Soto M; Bellido Guerrero D. Obesidad y esteatohepatitis no alcohólica: su interrelación y estudio. Rev Esp Obes. 2008(6)6:317-28.

  8. Patel AA, Torres DM, Harrison SA. Effect of weight loss on nonalcoholic fatty liver disease. J Clin Gastroenterol. 2009;43:970-4.

  9. Comar KM, Sterling RK. Reciew article: drug therapy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2006;23:207-15.

  10. Bayard M, Holt J, Boroughs E. Nonalcoholic fatty liver disease. Am Fam Physician. 2006;73:1961-9.

  11. Chan H, De Silva J, Leung N, Lim SG, Farrell G. The Asia-Pacific Working Party on NAFLD. How Should We Manage Patients With Non-alcoholic Fatty Liver Disease in 2007. J Gastroenterol Hepatol. 2007;22(6):801-8.

  12. Cheung O, Sanyal A. Recent Advances in nonalcoholic fatty liver disease. Curr Opin Gastroenterol. 2010;26(3):202-8.

  13. Sabuncu T, Nazligul Y, Karaoglanoglu M, Ucar E, Kilic F. The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis. Rom J Gastroenterol. 2010;12:189-92.

  14. Filippatos TD; Kiortsis DN, Liberopoulos EN, Mikhailidis DP, Elisaf MS. A review of the metabolic effects of sibutramine. Curr Med Res Opin. 2005;21(3):457-68.

  15. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, et al. Bariatric surgery: a systematic review and metaanalysis. JAMA. 2004;292:1724-37.

  16. Angelico F, Burattin M, Alessandri C, Del Ben M, Lirussi F. Fármacos que mejoran la resistencia insulínica para el hígado graso no alcohólico y la esteatohepatitis (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, número 3, 2008.

  17. Loomba R, Lutchman G, Kleiner DE, Ricks M, Feld JJ, Borg BB, et al Clinical trial: pilot study of metformin for the treatment of non-alcoholic Steatohepatitis Alimentary Pharmacology & Therapeutics. 2009;29(2):172-82.

  18. Lirussi F, Azzalini L, Orando S, Orlando R, Angelico F. Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database of Systematic Reviews. Issue 1. Art No: CD004996; 2007.

  19. Sanyal A. Pioglitazone vs. Vitamin E vs. Placebo for the Treatment of nondiabetic patients with nonalcoholic steatohepatitis (PIVENS) trial. N Engl J Med [Internet]. 2010 [citado: 27 de abril de 2010]. Disponible en: http://www.nejm.org/doi/full/10.1056/NEJMoa0907929#t=articleTop

  20. Orlando R, Azzalini L, Orando S, Lirussi F. Ácidos biliares para el hígado graso no alcohólico y la esteatohepatitis (revisión Cochrane traducida). En: La Biblioteca Cochrane Plus; 2008(4). Oxford Cochrane Plus [Internet]. 2007 [citado: 27 de enero de 2013]. Disponible en: http://www.update-software/CD005160.pdf

  21. Liu Q, Bengmark S, Qu S. The role of hepatic fat accumulation in pathogenesis of non-alcoholic fatty liver disease (NAFLD). Lipids in Health and Disease. 2010;9:42. Disponible en: http://www.lipidworld.com/content/9/1/42

  22. Satapathy S, Sakhuja P, Malhotra V, Sharma B, Sarin S. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinlammation in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol. 2007;22:634-8.

  23. Lubel J, Herath Ch, Burrell L, Angus P. Liver Disease and the Renin-angiotensin System: Recent Discoveries and Clinical implications. J Gastroenterol Hepatol. 2008;23(9):1327-38.

  24. Yokohama S, Yoneda M, Haneda M, Okamoto S, Okada M, Aso K, et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology. 2004;40:1222-5.

  25. Miccoli R, Bianchi C, Penno G, Del Prato S. Insulin resistance and lipid disorders. Future lipidology. 2008;3(6):651-64.

  26. Riley P, Sudarshi D, Johal M, Benedict A, Panteli J, et al. Weight loss, dietary advice and statin therapy in non-alcoholic fatty liver disease: a retrospective study. Int J Clin Pract. 2008;62(3):374-81.

  27. Lirussi F, Mastropasqua E, Orando S, Orlando R. Probióticos para el hígado graso no alcohólico y/o la esteatohepatitis (revisión Cochrane traducida). 2010(1). En: La Biblioteca Cochrane Plus. 2008.

  28. Younossi ZM. Current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2008;28(1):2-12.

  29. Lu L, Zeng M, Mao Y, Chen C, Fu Q, Wang J, et al. Diisopropylamine dichloroacetate in the treatment of nonalcoholic fatty liver disease: a multicenter random double-blind controlled trial, Chinese J Hepatol. 2005;13:92-5.

  30. Chande N, Laidlaw M, Adams P, Marotta P. Yo Jyo Hen Shi Ko (YHK) improves transaminases in nonalcoholic steatohepatitis (NASH): a randomized pilot study. Dig Dis Sci. 2006;51:1183-9.

  31. Shang J, Chen L, Xiao F, Sun H, Ding H, Xiao H. Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase. Acta Pharmacol Sin. 2008;29:698-706.

  32. Ochiai H, Ooka H, Shida C, Ishikawa T, Inoue D, Okazaki R. Acarbose treatment increases serum total adiponectin levels in patients with type 2 diabetes. Endocr J. 2008;55:549-56.

  33. Salama R, Nassar A, Nafady A, Mohamed H. A novel therapeutic drug (Copper Nicotinic Acid Complex) for non-alcoholic fatty liver; Liv Internat. 2007;27(4):454-64.

  34. Vilar Gómez E, Rodríguez de Miranda A, Gra Oramas B, Arús Soler E, Llanio Navarro R, Calzadilla Bertot L, et al. Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2009;30:999-1009.

  35. Gutiérrez-Grobe Y, Villalobos-Blázquez I, Canizales-Quinteros S. A Pnpla-3 gene polymorphism is associated with nonalcoholic fatty liver disease (NAFLD) in Mexican patients. New Orleans, Louisiana: Program and abstracts of Digestive Disease Week (DDW). May 1-5, 2010; Poster S1855.




2020     |     www.medigraphic.com